Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CLNN
CLNN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CLNN News
Clene Plans to Submit ALS Drug Application
May 15 2026
stocktwits
Clene Reports Q1 2026 Financial Results with Significant Cash Position
May 14 2026
seekingalpha
Clene Prices $7 Million Direct Stock Offering
May 05 2026
seekingalpha
Clene Plans NDA Submission by Q3 2026 for ALS Treatment
May 04 2026
stocktwits
Clene Plans NDA Submission for ALS Drug CNM-Au8
May 04 2026
Newsfilter
Clene Reports FY 2025 Financial Results with Significant Losses
Mar 12 2026
seekingalpha
Clene Inc. Outlines Key Milestones for 2026
Feb 24 2026
Yahoo Finance
Clene Inc. to Present at Emerging Growth Conference on January 21, 2026
Jan 16 2026
Globenewswire
Clene Inc. to Present at Emerging Growth Conference on January 21, 2026
Jan 16 2026
Newsfilter
China SXT Pharmaceuticals (SXTC) Closes $10 Million Offering, Stock Rises 17.4%
Jan 14 2026
NASDAQ.COM
Clene Inc. Receives FDA Approval for In-Person Meeting in 2026, NfL Reductions Linked to Lower ALS Mortality Risk
Jan 12 2026
Globenewswire
Clene Inc. Receives FDA Approval for In-Person Meeting in 2026, NfL Reduction Significantly Lowers ALS Mortality Risk
Jan 12 2026
Newsfilter
Clene Inc. Secures $28 Million Financing to Advance ALS Drug Development
Jan 09 2026
Globenewswire
Clene Insider Offloads Shares Valued at $1,725,735, Per Recent SEC Filing
Dec 18 2025
Yahoo Finance
88th Emerging Growth Conference Scheduled for December 10-11, 2025
Dec 10 2025
Globenewswire
Clene Set to Deliver Important Update on CNM-Au8 for Amyotrophic Lateral Sclerosis
Dec 03 2025
NASDAQ.COM
Show More News
